SNGX experienced a massive 86% revenue collapse while R&D expenses surged 43%, leading to significantly deeper losses despite improved cash position.
The dramatic revenue decline from $839K to $119K suggests either loss of major contracts or severe operational challenges in their commercial activities. While the company has strengthened its cash position to $26M and reduced current liabilities, the widening losses and increased R&D spending indicate heavy investment in clinical trials without corresponding revenue generation.
SNGX's financials show a company in significant transition with revenue collapsing 86% while R&D expenses jumped 43% to $7.5M, resulting in net losses deepening from -$8.3M to -$11.1M. The balance sheet improved with cash rising 39% to $26M and current liabilities declining 24%, suggesting recent capital raising activities. Overall, this presents a classic biotech profile of a company burning cash on clinical development while commercial revenues evaporate, though the improved cash position provides near-term runway.
Revenue declined 85.8% — significant demand weakness or market share loss warrants investigation.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Deposits declined 75% — significant outflows warrant immediate investigation into funding stability.
R&D investment increased 43.3% — signals commitment to future product development, though near-term margin impact.
Cash position surged 39.4% — strong cash generation or capital raise providing significant financial cushion.
Net income declined 34% — review whether driven by operations, interest costs, or non-recurring items.
Equity base grew 28.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Current liabilities reduced — improved short-term financial position and working capital health.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →